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Summary 
Background and purpose: the hematopoietic activity of erythropoietin (EPO) is mediated by the 
classic EPO receptor (EpoR) homodimer, whereas the tissue-protective effects by a hetero-complex 
between EpoR and the β-common receptor (βcR). Here, we investigated the effects of a novel, 
selective ligand of the hetero-complex EpoR/βcR (pyroglutamate helix B surface peptide [pHBSP]) 
in mice chronically exposed to a diet enriched in sugars and saturated fats. 
Experimental approach: male C57BL/6J mice maintained on high-fat high-sucrose diet (HFHS) 
for 22 weeks. pHBSP (30 µg/kg s.c.) was administered for the last 11 weeks.  
Key results: mice fed the HFHS diet exhibited insulin resistance, hyperlipidemia, hepatic lipid 
accumulation and kidney dysfunction. In the gastrocnemius muscle, HFHS impaired the insulin-
signaling pathway and reduced GLUT-4 membrane translocation and glycogen content. 
Administration of pHBSP ameliorated renal function, reduced hepatic lipid deposition and 
normalized serum glucose and lipid profiles. These effects were associated with a significant 
improvement in insulin sensitivity and glucose uptake in the skeletal muscle. Diet-induced 
overproduction of the myokines interleukin-6 and fibroblast-growth-factor-21 were attenuated by 
pHBSP and, most importantly, pHBSP markedly enhanced muscle mitochondrial biogenesis.  
Conclusions and implications: this is the first report that chronic treatment with an EPO-derivative 
devoid of any hematopoietic effects triggers an amelioration of the HFHS-induced metabolic 
abnormalities by affecting multiple levels of the insulin signaling and inflammatory cascades within 
the mouse skeletal muscle while enhancing mitochondrial biogenesis. 
 
Keywords: erythropoietin, pyroglutamate helix B surface peptide, β-common receptor, high-fat 
high-sucrose diet, insulin resistance, insulin signaling pathway, myokines, inflammation 
Abbrevetions: βcR: β-common receptor; ACR: albumin-to-creatinine ratio; BUN: blood urine 
nitrogen; COI: cytochrome c oxidase 1; EPO: erythropoietin; EpoR: EPO receptor; GLUT-4: 
glucose transporter type 4; HFHS: high-fat high sugar; mtTFA: mitochondrial transcription factor 
A; NRF1: nuclear respiratory factor 1; OGTT: oral glucose tolerance test; PGC1-α: peroxisome 
proliferator-activated receptor γ co-activator 1-α; pHBSP: pyroglutamate helix B surface peptide; 
PVDF: polyvinyldenedifluoride; TG: triglyceride 
INTRODUCTION 
Erythropoietin (EPO), a 31 kDa glycoprotein that stimulates proliferation, differentiation and 
survival of erythroid progenitor cells by activation of the EPO receptor (EpoR), has been widely 
used for the treatment of chronic anemia (Drueke et al., 2006). A large number of experimental 
studies demonstrate a tissue-protective effect of EPO in the brain, the kidney, the heart, the 
vasculature and the gastrointestinal tract, to name but a few (Patel et al., 2011). Interestingly, EPO 
deficiency has been documented in patients with diabetes  (Craig et al., 2005; McGill et al., 2006; 
Thomas, 2006), and EPO therapy has been reported to decrease insulin resistance in hemodialysis 
patients by improving glucose metabolism and reducing chronic inflammation (Khedr et al., 2009; 
Mak, 1998; Rasic-Milutinovic et al., 2008; Spaia et al., 2000). Collectively, these data raised the 
possibility that EPO and the signaling cascades activated by the pleiotropic hormone may 
significantly affect insulin sensitivity and, thus, may be relevant for management of diabetes. 
Potentially serious adverse effects of EPO including an increase in hematocrit, blood pressure and 
thrombosis may limit any potential therapeutic translation of these beneficial effects of EPO in 
diabetic patients. Although the EPO-mediated signaling pathways are well characterized for 
erythroid cell types, they are less well defined for non-erythroid tissues and, therefore, there is 
limited information about the mechanisms underlying the EPO-induced improvements in insulin 
resistance. The extra-hematopoietic effects of EPO have been suggested to be mediated, at least in 
part, by a putative “tissue-protective receptor”, that has been recently proposed to be a hetero-
complex between the EpoR and the β-common receptor (βcR, known also as CD131) (Brines et al., 
2004). βcR is a common subunit of other heteroreceptors, including those of interleukin (IL)-3, IL-5 
and granulocyte-macrophage colony stimulating factor (Murphy et al., 2006). Very recently, the use 
of βcR knockout mice has led to the demonstration that the activation of βcR by EPO is essential 
for the EPO-induced reduction of both kidney and cardiac dysfunction associated with sepsis, as 
well as in producing long-term relief of neuropathic pain (Coldewey et al., 2013; Khan et al., 203; 
Swartjes et al., 2011). Moreover, the development of EPO-derivatives, which only activate the 
EpoR-βcR complex and do not stimulate erythropoiesis, has led to a better characterization of the 
role of this pharmacological target in mediating EPO effects (Leist et al., 2004). The pyroglutamate 
helix B surface peptide (pHBSP), also known as ARA290, is the newest generation EPO derivative, 
which mimics the external, aqueous face of helix B of EPO (including amino acids that are exposed 
at the helix B surface as well as three residues from the loop between helices B and C), sufficiently 
to exert the tissue-protective activities seen with the EPO protein. Thus, pHBSP is a small synthetic 
peptide consisting of eleven amino acids, which binds to the EpoR-βcR complex, but not the 
classical erythropoietic EpoR homodimer in vitro (Brines et al., 2008a). Several preclinical studies 
have revealed that pHBSP exerts pronounced tissue-protective properties without stimulating 
hematopoiesis (Brines et al., 2008b; McVicar et al., 2011; Pulman et al., 2013; Seeger et al., 2011; 
Swartjes et al., 2011; van Rijt et al., 2013). However, none of the previous studies investigated the 
role of the EpoR-βcR complex activation in the management of metabolic abnormalities or any 
other chronic disease where administration of the drug for several weeks is warranted. Hence, the 
present study was undertaken to determine the effects of the non-erythropoietic EPO derivative 
pHBSP in mice chronically exposed to a diet enriched in sugars and saturated fats, which are known 
to promote obesity and insulin resistance. To provide a characterization of the extra-hematopoietic 
effects of EPO, we investigated the potential effects of the activation of the EpoR-βcR complex by 
pHBSP on signaling pathways involved in the pathogenesis of insulin resistance, focusing on the 
skeletal muscle, which accounts for ~70–80% of the insulin-stimulated glucose uptake and, thus, 
exerts a key role in regulating whole body glucose homeostasis. 
METHODS 
 
Animal model 
Male C57BL/6J mice, aged 4 weeks, were purchased from Harlan Laboratories (Udine, Italy). The 
animals were maintained on a pellet diet (Piccioni n.48, Gessate Milanese, Italy) for 1 week, then 
randomly divided into two groups: normal diet (control, n = 18) and high-fat high sugar diet 
(HFHS, n = 24) for 22 weeks. The HFHS diet contained 40% fat (2% from soybean, 38% from 
butter), 15% protein, 45% carbohydrate (15% from corn starch and 30% from sucrose). The animals 
were housed in a temperature-controlled environment with a 12 h light/dark cycle. Food and water 
consumption and body weight were measured weekly. The experimental protocol was approved by 
by the Turin University Ethics Committee. All studies involving animals are reported in accordance 
with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al., 2010; 
McGrath et al., 2010).  
 
Treatments 
After 11 weeks on diet, 6 mice on control diet and 12 mice on HFHS diet were treated with pHBSP 
(30 µg/kg, in 200 µl PBS) for further 11 weeks (control+pHBSP and HFHS+pHBSP, respectively). 
The EPO derivative pHBSP was supplied by Araim Pharmaceuticals (Ossining, NY, USA). Mice 
were dosed by s.c. injection at two-day interval. Vehicle treatment consisted of 200 µl PBS at pH 
7.4.The pHBSP dose used in this study is based on previous studies on tissue protective effects of 
chronic pHBSP administration in mice (Brines et al., 2008b; Schmidt et al., 2011; Swartjes et al., 
2011). This dosage of pHBSP was previously found to induce no change in the hematocrit, 
hemoglobin concentration and platelet count over a 28-day period of twice daily administration 
(Brines et al., 2008b). The interval of drug administration was based on published preclinical and 
clinical data (Heij et al., 2012; Swartjes et al., 2011; van Velzen et al., 2014), which clearly 
demonstrate that the repetitive (2-day intervals) i.p. administration of pHBSP exerts significant 
beneficial effects, despite its short half-life (t1/2 ELIM ∼2 min). 
 
Oral glucose tolerance test (OGTT). 
OGTT was done on mice fasted for 6 h at the end of the experiment (week 22). Glucose (2 g/kg) 
was given orally by gavage. Serial blood glucose measures were taken at 0, 30, 60, 90, and 120 min 
from the saphenous vein using the Accu-Check glucometer (Roche Diagnostics, Germany).  
 
Biochemical parameters.  
Urine was collected for analysis by placing animals in metabolic cages for 18 h. The concentration 
of urine creatinine and albumin was assessed using commercial kits (Arbor Assays, USA and 
Bethyl Laboratories Inc.,USA, respectively). Albumin excretions were related to urine creatinine 
concentrations (albumin-to-creatinine ratio, ACR) in order to take into account differences in 
urinary flows. Blood urine nitrogen (BUN) levels as well as plasma concentrations of triglycerides, 
total cholesterol, high-density-lipoprotein (HDL), and low density-lipoprotein (LDL) were 
determined using colorimetric assays from Sigma Chemical (USA) and Hospitex Diagnostics 
(Italy), respectively. Commercially available ELISA kits were used to measure plasma insulin, 
leptin, adiponectin, IL-6 and FGF-21 levels.  
 
Kidney histopathological examination 
Coronal sections of both kidneys and fragments from the left lateral and medial lobes were fixed in 
4% buffered formaldehyde solution overnight at 4° C. Dewaxed 5 μm sections were stained with 
hematoxylin-eosin and examined under an Olympus Bx4I microscope (40x magnification) with an 
AxioCamMR5 photographic attachment (Zeiss, Gottingen, Germany).  
 
Liver Oil Red staining 
Neutral lipids were assessed on sections of frozen liver embedded in OCT (10 μm in thickness) by 
Oil Red O staining using an Olympus Bx4I microscope (40x magnification) with an AxioCamMR5 
photographic attachment (Zeiss, Gottingen, Germany).  
 
Protein extraction and western blot 
Gastrocnemius and liver were homogenized and fractioned as previously described (Benetti et al., 
2013). Briefly, frozen tissues were homogenized in RIPA buffer containing protease inhibitors. The 
protein content was measured by a protein assay kit using bicinchoninic acid and albumin as 
standard (Pierce Biotechnology Inc., USA). Protein-matched samples were electrophoresed, and 
then transferred to a polyvinyldenedifluoride (PVDF) membrane, which was then incubated with 
primary antibodies (GLUT-4, COI, PGC-1α, mtTFA, NRF-1, and the total and phosphorylated 
forms of IRS-1, Akt, GSK-3β and AS160; Santa Cruz Biotechnology Inc.). After incubation with 
primary antibodies, membranes were incubated with secondary antibodies linked to horseradish 
peroxidase. Protein bands were visualized using enhanced chemiluminescence. For control of 
protein loading, the blots were stripped and reacted with tubulin monoclonal antibody. Bands were 
quantified by an optical densitometry using Gel ProAnalyzer 4.5, 2000 software (Media 
Cybernetics, Silver Spring, MD, USA).  
 
Liver triglyceride (TG) level 
Lipids were extracted from liver tissue as previously described (Collino et al., 2013) and TG 
contents were determined enzymatically by using a TG quantification kit from Abnova Corporation 
(Germany). 
 
Skeletal muscle glycogen content. 
The glycogen concentration of the gastrocnemius was determined using a glycogen assay kit, 
following the protocol provided by the manufacturer (Glycogen Assay Kit, Abnova Corporation, 
Taiwan). 
 
EpoR/βcR co-immunoprecipitation. 
Co-immunoprecipitation was performed in order to examine whether there is a physical interaction 
between EpoR and βcR. Protein extracts were immunoprecipitated from gastrocnemius lysates 
using EpoR antibody for 3 hours, followed by incubation with protein A-agarose beads overnight at 
4°C. The mixture was centrifuged for 5 minutes and supernatants were removed. Bead-antibody-
protein complexes were washed in RIPA buffer and proteins were eluted from protein A-agarose 
beads by boiling in loading buffer. After centrifuge antigen-antibody complexes were subjected to 
SDS-PAGE using 8% gel, followed by transfer to PVDF membranes. The membranes were 
incubated with the primary antibodies anti-EpoR or anti- βcR and the appropriate secondary 
antibodies. 
 
Immunohistochemical staining 
Representative 10-µm cryostat sections of gastrocnemius were fixed with 100% acetone for 10 min 
and then incubated with rabbit anti-glucose transporter type 4 (GLUT-4) antibody overnight at 4°C. 
After washing, sections were incubated with anti-rabbit IgG-HRP for 1h at room temperature. Color 
development was achieved by incubation with 0.02% 3,3′-diaminobenzidine tetrahydrochloride 
containing 0.02% hydrogen peroxide for 10 minutes at room temperature and the specific staining 
visualized with Olympus-Bx4I microscope connected by a photographic attachment (Carl Zeiss, 
Oberkochen, Germany).  
 
Statistical analysis.  
We analyzed data using the Prism software package (GraphPad Software). Comparisons among 
groups were performed using one-way analysis of variance with Bonferroni's multiple comparison 
post hoc test. All values are presented as mean ± S.E.M. for n observations. Differences among 
groups were considered statistically significant at p values below 0.05. 
RESULTS 
Effects of diet exposure and pHBSP treatment on metabolic parameters. 
After 22 weeks of feeding, mice of the HFHS group had greater body and adipose tissue 
(epididymal fat) weights than control diet-fed animals, which were significantly reduced by pHBSP 
treatment (Table 1). Moreover, an increase in the caloric intake in the mice fed with the 
experimental diet was recorded and this increase was slightly reduced by drug treatment without 
reaching statistical significance. As reported in Table 2, HFHS increased serum levels of 
triglycerides, total cholesterol and LDL and reduced HDL level, in comparison with control mice. 
Most notably, the changes in lipid contents were normalized by pHBSP treatment. When compared 
to control, chronic exposure to HFHS resulted in more than two-fold increase in insulin levels, 
which was associated with almost 30% increase in fasting serum glucose concentrations (Figure 1A 
and 1B). Consistently, the OGTT revealed that the HFHS mice were glucose intolerant (Figure 1C). 
In contrast, pHBSP administration exerted significant insulin- and glucose-lowering ability. Serum 
concentrations of adiponectin and leptin, both of which play important roles in lipid and glucose 
homeostasis, showed different patterns: while the level of adiponectin in HFHS mice was lower 
than in control mice, that of leptin increased versus controls (Table 2). When pHBSP was 
administered to HFHS mice, there was a significant increase in the adiponectin levels, associated 
with a significant decrease in leptin levels, while pHBSP administration to mice fed with the control 
did not modify any of the above described metabolic parameters. 
 
Chronic pHBSP treatment reduces diabetic nephropathy in HFHS mice. 
Representative pictures from each experimental group were taken from the transition between the 
deeper cortex and the outer stripe of the outer medulla zones (Figure 2A). Kidneys from mice fed 
with a standard laboratory chow showed a normal appearance and treatment of control mice with 
pHBSP did not produce any significant morphological alterations. In contrast, the HFHS diet 
produced an intense vacuolar degeneration of the S1 and S2 portions of the proximal convoluted 
tubules, which may be the consequence of specific features of these segments, including prominent 
endocytic system and large secondary lysosomes (Maunsbach, 1966). In contrast, the normal 
appearance of the S3 segments (Supplemental Figure 1) could be the result of a lesser development 
of the endocytic vacuolar system of the “pars recta". Interestingly, the HFHS-induced alterations 
were significantly attenuated by pHBSP treatment. The HFHS-induced renal pathology correlated 
with decline in kidney function. The ACR ratio, a reliable marker of glomerular damage and 
progressive renal dysfunction associated with diabetes and obesity (Praga et al., 2010), was 
remarkably elevated in HFHS-fed mice and significantly reduced after pHBSP administration for 11 
weeks (Figure 2B). Similarly, BUN levels were markedly increased in the HFHS group compared 
with the control group and significantly reduced by pHBSP treatment (Figure 2C) 
 
Chronic pHBSP treatment reduces liver steatosis. 
Livers from control mice showed a normal appearance, and chronic treatment with pHBSP had no 
effect on liver histology. In contrast, livers from mice that had received the HFHS diet showed 
moderate to severe mixed vacuolar steatosis (Figure 3A and Supplemental Figure 2). The observed 
steatosis was more prominent in the periportal zone, where hepatocytes exhibited some degree of 
hydropic degeneration. Chronic administration of pHBSP attenuated the neutral fat accumulation 
(measured after Oil Red O staining; Figure 3A). This beneficial effect of pHBSP on lipid 
accumulation was confirmed by measurement of TG content (Figure 3B). Liver homogenates from 
HFHS mice showed a 3-fold increase in TG levels when compared to control animals. Most 
notably, the TG levels of HFHS animals that had been treated with pHBSP were similar than those 
seen in control animals. 
 
Insulin signal transduction was enhanced in gastrocnemius muscle of HFHS mice exposed to 
pHBSP treatment. 
In the skeletal muscle, the expression levels of total IRS-1, Akt and GSK-3β proteins were not 
affected by either dietary manipulation or drug treatment (Figure 4). In contrast, 22 weeks of HFHS 
diet caused a marked increase in Ser307 phosphorylation of IRS-1 in parallel with reduced Ser473 
phosphorylation of Akt and Ser9 phosphorylation of GSK-3β, a downstream target of Akt, thus 
indicating impaired insulin signaling pathway. Chronic pHBSP administration significantly 
counterbalanced all the effects of HFHS diet on IRS-1, Akt and GSK-3β phosphorylation. 
 
GLUT-4 and glycogen levels in the mouse skeletal muscle. 
As shown in Figure 5B, GLUT-4 expression was slightly (although not significantly) reduced in 
gastrocnemius of HFHS mice compared to control animals, and increased following pHBSP 
administration. Interestingly, pHBSP administration not only increased carrier expression levels, 
but also induced a significant membrane translocation, as shown by a different pattern of GLUT-4 
immunostaining between muscle sections of mice exposed to dietary manipulation in the absence or 
presence of pHBSP (Figure 5A). GLUT-4 translocation to the plasma membrane was confirmed by 
Western blot analysis of the Akt substrate 160 (AS160), a protein that regulates insulin-stimulated 
GLUT-4 trafficking in skeletal muscle (Kramer et al., 2006). AS160 phosphorylation is required for 
GLUT-4 translocation to the cell surface. Here we showed that the total protein abundance of 
AS160 in the mouse gastrocnemius was not affected by either dietary manipulation or drug 
treatment. However, Thr642 phosphorylation of AS160 was significantly reduced by HFHS diet and 
this effect was prevented by pHBSP administration (Figure 5C). The HFHS-induced modulation of 
GLUT-4 membrane translocation was accompanied by a robust decrease in muscle glycogen 
content, which was blunted by pHBSP treatment (Figure 5D).  
 
Administration of pHBSP prevented local and systemic myokine overproduction evoked by 
chronic consumption of HFHS. 
HFHS significantly elevated skeletal muscle production of two well-known myokines, IL-6 and 
FGF-21, while pHBSP treatment resulted in a massive decrease in IL-6 and a slight reduction in 
FGF-21 levels (Figure 6A and 6B, respectively). These changes in the muscle myokine production 
were paralleled by the changes in myokine circulating levels. In fact, circulating concentrations of 
IL-6 and FGF-21 increased after HFHS feeding and these increases were almost completely 
abolished in mice treated with pHBSP. In contrast, their levels were not altered by pHBSP 
treatment in mice fed with the control diet (Figure 6C and 6D).  
 
Effect of chronic pHBSP treatment on markers of muscle mitochondrial production/biogenesis. 
To get further insight toward the effects of pHBSP, selective markers of muscle mitochondrial 
production/biogenesis were evaluated. Protein expression of the mitochondrial component of the  
electron transfer cytochrome c oxidase 1 (COI), used as a marker of mitochondrial content, and 
peroxisome proliferator-activated receptor γ co-activator 1-α (PGC1-α), a transcriptional 
coactivator mediating mitochondrial biogenesis, increased in the gastrocnemius muscle of animals 
fed with the HFHS diet (Figure 7A and 7B, respectively). Interestingly, a further increase in PGC1-
α expression was observed in the muscle of HFHS mice treated with pHBSP. Moreover, expression 
of the mitochondrial transcription factor A (mtTFA) and nuclear respiratory factor 1 (NRF1), which 
act in concert to increase mitochondrial oxidative phosphorylation and mitochondrial biogenesis, 
were not affected by HFHS diet, whereas they were markedly up-regulated by pHBSP (Figure 7C 
and 7D, respectively). 
 
Evidence of an heteromeric complex consisting of EpoR and βcR in the mouse skeletal muscle. 
Immunoprecipitation assay showed that EpoR and βcR were physically associated in the 
gastrocnemius muscle of control animals and this interaction was not altered in response to dietary 
modification and/or pHBSP treatment (Figure 8). 
DISCUSSION 
The current study demonstrates for the first time that chronic administration of the EPO-derivative 
pHBSP protects against the metabolic abnormalities caused by exposure to a typical unhealthy diet 
containing high concentrations of both fat and sugar. Mice fed with a HFHS diet for 22 weeks 
developed a significant increase in body weight associated with dyslipidaemia, hyperinsulinaemia, 
and changes in insulin sensitivity and, most notably, treatment with pHBSP normalized serum 
glucose and lipid profiles and evoked a slight, but still significant, decrease in body weight, with 
reduced amounts of epydidimal fat tissue. This decrease was not due to reduced food intake, as this 
parameter was measured and ruled out. In addition, we observed several pathophysiological 
alterations in kidney(s) and liver of mice that had been maintained on the HFHS diet, which were 
significantly attenuated by drug treatment. In HFHS-animals, pHBSP reduced the diet-induced 
diabetic nephropathy (confirmed by histology,  rise in BUN levels and albuminuria). Similarly, 
pHBSP reduced the HFHS-induced liver steatosis (confirmed by histological analysis and 
determination of tissue TG levels). Overall, our data are in keeping with recent studies showing that 
EPO may ameliorate organ dysfunction evoked by metabolic derangements and regulate glucose 
metabolism and insulin sensitivity. Specifically, treatment of diabetic mice with EPO attenuated 
both albuminuria and podocyte loss (Loeffler et al., 2013) and improved mitochondrial oxidative 
phosphorylation and lipid metabolism in the liver (Meng et al., 2013). Interestingly, transgenic mice 
constitutively overexpressing human EPO are resistant to high fat diet-induced glucose intolerance 
and insulin resistance (Hojman et al., 2009; Katz et al., 2010). These data are supported by clinical 
evidence documenting beneficial effects of EPO on both glucose metabolism and insulin sensitivity 
in both diabetic and non-diabetic patients undergoing hemodialysis (Allegra et al., 1996; Brown et 
al., 2009; Khedr et al., 2009; Tuzcu et al., 2004). However, thus far any potential therapeutic 
applications of human recombinant EPO in patients with metabolic diseases are limited by rises in 
hematocrit and platelet count (hematopoietic effect), resulting in an increase in thrombotic risk. The 
EPO-mimetic pHBSP, which was evaluated in our study, binds selectively to the heteromeric 
receptor composed of EpoR and βcR, which is responsible for the tissue-protective effects of EPO, 
but does not interact with the erythropoietic EpoR homodimer, activation of which triggers a rise in 
hematocrit (Brines et al., 2008a). Therefore, our findings confirm the metabolic protective effects of 
EPO against diet-induced metabolic derangements and, most notably, demonstrate that these 
beneficial metabolic effects can also be obtained by selective activation of the EpoR-βcR complex, 
without stimulating hematopoiesis and, hence, potentially causing the severe side-effects associated 
with chronic EPO administration. 
The skeletal muscle, which is a major site of postprandial glucose metabolism and one of the 
insulin-sensitive tissues most likely to manifest early signs of insulin resistance, is a main target of 
the protective effects of EPO. EPO is produced by primary myoblasts isolated from gastrocnemius 
muscle and it contributes to improve myoblast proliferation and survival as well as skeletal muscle 
repair and regeneration by activating the Akt signaling pathway (Jia et al., 2012). EPO 
overexpression in skeletal muscle protects mice against diet-induced obesity and associated 
metabolic abnormalities (Hojman et al., 2009). Davenport et al. also demonstrated that 14 weeks of 
EPO administration in patients with chronic kidney disease on hemodialysis increased muscle 
glycogen content (Davenport et al., 1993), while in rats EPO induced a shift in muscle fiber 
composition from fast glycolytic fibers to slow oxidative fibers (Cayla et al., 2008). Both EpoR and 
βcR are expressed in human skeletal muscle and are co-localized in the sarcolemma (Joshi et al., 
2013). Here we describe for the first time the physical interaction between EpoR and βcR in the 
mouse skeletal muscle by immunoprecipitation assay, showing that the pharmacological target of 
pHBSP, the EpoR/βcR complex, is expressed in the skeletal muscle of both control and HFHS-fed 
mice. pHBSP is known to bind the EpoR/βcR complex (Bohr et al., 2013; Brines et al., 2008a; 
Brines et al., 2012) and no effect of pHBSP in mice lacking the βcR has been reported (Swartjes et 
al., 2011; Swartjes et al., 2013). However, further studies on the effects of pHBSP in βcR knock out 
mice subjected to HFHS diet are warranted to confirm that the observed beneficial effects of this 
peptide are indeed due to activation of the EpoR/βcR complex. 
In our study, pHBSP attenuated the impairment in insulin signaling, caused by HFHS-diet in 
skeletal muscle, which may, at least in part, account for the changes in systemic insulin sensitivity. 
Specifically, pHBSP counteracted the HFHS-induced alterations in the phosphorylation of IRS-1 
protein in the skeletal muscle, as well as the activities of the downstream key insulin signaling 
molecules, Akt and GSK-3β, an Akt substrate. These effects were accompanied by a significant 
improvement in membrane translocation of GLUT-4, the most abundant glucose transporter isoform 
in skeletal muscle (Bouzakri et al., 2006), and by a robust increase in muscle glycogen content. As 
the inhibition of GSK-3β evokes an increase in the glycogen synthesis (Cross et al., 1995), we 
speculate that the increased muscle glycogen storage evoked by pHBSP administration may be 
secondary to selective inactivation of GSK-3β. Similarly, the pHBSP-induced membrane 
translocation of GLUT-4 could be secondary to the modulation of the insulin-signaling pathway by 
activation of EpoR/βcR complex. Indeed, both Akt and IRS-1 may regulate the translocation, 
targeting and fusion of GLUT-4-containing vesicles in mice skeletal myocytes (Gonzalez et al., 
2006; Leto et al., 2012; Zeng et al., 2012). Akt also regulates AS160 phosphorylation, which is a 
crucial step in GLUT-4 translocation in the skeletal muscle (Kramer et al., 2006; Sano et al., 2003), 
and here we showed a significant increase in the phosphorylation of AS160 in the presence of 
pHBSP, which may result in GLUT-4 exocytosis and reduced GLUT-4 endocytosis. We propose 
that pHBSP stimulates glucose transport in skeletal muscle by increasing AS160 phosphorylation 
throughout Akt modulation, thus implying that the EpoR/βcR complex is a common target of 
convergence to counteract both diet-induced impaired insulin signal transduction and glucose 
transport.  
Compelling evidence has occurred over the past few years that the skeletal muscle is an endocrine 
organ that produces and releases a number of biologically active substances, such as IL-6, IL-8, IL-
15, and FGF-21, collectively known as myokines (Pedersen et al., 2008). These myokines 
participate in cell-to-cell and organ-to-organ cross-talk and play important roles in the development 
of diseases associated with low-grade inflammation, including insulin resistance (Pedersen, 2011). 
Here we found that HFHS diet evoked up-regulation of IL-6 and FGF-21 in the skeletal muscle and 
that this effect was also associated with a strong increase in the plasma levels of IL-6 and FGF-21. 
Interestingly, administration of pHBSP led to dramatic reduction in the plasma levels of IL-6 and 
FGF-21. When measured in the gastrocnemius homogenates, however, the reduction in myokine 
levels by pHBSP was maximal for IL-6 and modest for FGF-21. This observation is intriguing, as 
the role of myokines in the etiology of insulin resistance has been matter of controversy. While 
chronic exposure to IL-6 produces insulin resistance in skeletal muscle both in vitro and in vivo 
(Nieto-Vazquez et al., 2008), FGF-21 has emerged as an important regulator of glucose 
metabolism, increasing glucose uptake and abolishing insulin resistance in skeletal muscle cells (Ni 
et al., 2012). In humans, serum FGF-21 levels are paradoxically increased in metabolic diseases 
(Chen et al., 2008; Galman et al., 2008; Han et al., 2010). The mechanisms responsible for this 
paradoxical elevation of FGF-21 are not fully understood, although it might be partly explained by a 
compensatory overexpression of FGF-21 and/or FGF-21 resistance in peripheral tissues with insulin 
resistance. We may, thus, speculate that the HFHS-induced rise in IL-6 recorded in our study 
contributes to compromise local insulin sensitivity, while the rise in FGF-21 is a defensive 
mechanism to counteract the deleterious effects of glucotoxicity. Accordingly, the reduction in IL-6 
levels by pHBSP might be a consequence of the EpoR/βcR complex activation, which exerts 
beneficial impact on insulin sensitivity. In contrast, FGF-21 levels were not directly modulated by 
pHBSP. Thus, the FGF-21 reduction afforded by pHBSP may well be secondary to a reduced 
glucotoxicity following pHBSP, but this hypothesis warrants further investigation. It is noteworthy 
that our results do not argue against the role of EPO as potential regulator of adipose tissue 
inflammation in diet-induced obesity and insulin resistance, as recently suggested by Alnaeeli et al 
(Alnaeeli et al., 2014). Instead, our report implicates that modulation of local inflammation in 
skeletal muscle may be an additional mechanism by which the EPO derivative affect the actions of 
insulin in skeletal muscle.  
Finally, we evaluated the effects of pHBSP on skeletal muscle mitochondrial function. Although 
mitochondrial dysfunction has been indicated as a cardinal feature of insulin resistance, most recent 
evidence suggest that an high caloric intake may develop insulin resistance, even in the presence of 
increased mitochondrial production in muscle (Garcia-Roves et al., 2007; Hancock et al., 2008). 
Our results show that HFHS feeding resulted in increases in skeletal muscle expression of COI and 
PGC-1α, although no effects were observed on the expression of NRF1 (a transcription factor 
involved in controlling the expression of nuclear genes encoding for mitochondrial proteins) and 
mtTFA (a transcription factor involved in controlling the expression of mitochondrial genes) (Hock 
et al., 2009; Scarpulla, 2008). This slight increase in selective markers of mitochondrial number 
and/or function detected in the skeletal muscle of HFHS mice may be suggestive of an early and 
weak compensatory mechanism to the deleterious consequences of dietary manipulation, which was 
dramatically improved in response to the activation of the EpoR/βcR complex, as shown by a 
further induction in PGC-1α expression as well as a robust up-regulation of NRF1 and mtTFA in 
the presence of chronic pHBSP administration.  
In conclusion, chronic treatment with pHBSP, an EPO-derivative devoid of any hematopoietic 
effects, triggers an amelioration of the metabolic abnormalities evoked by exposure to a diet 
containing high concentrations of both fat and sugar. The present study also increases our 
understanding of the mechanism of action of pHBSP and highlights a pivotal role for the muscle 
EpoR/βcR complex as a key interface between impaired insulin pathway and local inflammatory 
response. The demonstration that an EPO derivative that is devoid of any erythropoietin activity 
(that are, hence, potentially translatable to man) may act on diet-induced metabolic derangements 
points to a new pathway for the development of novel drugs for patients with diabetes and obesity, 
two closely linked healthcare challenges of modern societies that continue to rise in prevalence, 
with important health and economic implications. 
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 TABLE 1 
Effects of diet and pHBSP chronic administration on metabolic parameters 
 
Control 
(n = 12) 
Control+pHBSP 
(n = 6) 
HFHS 
(n = 12) 
HFHS+pHBSP 
(n = 12) 
Body weight, g  29.05±0.58§ 28.7±1.21§ 38.00±0.82* 34.7±0.73*§ 
Body weight gain, g  9.17±0.75§ 8.14±1.67§ 16.21±1.51* 10.03±1.90§ 
Food intake, g/die 3.80±0.40 3.20±0.50 2.90±0.40 2.70±0.40 
Caloric intake (kcal/die) 10.80±0.92§ 9.92±1.55§ 14.05±0.80* 12.25±0.80 
Epididymal fat weight (%BW) 2.41±0.09 2.11±0.21 3.34±0.25* 2.52±0.25§ 
Kidney weight (%BW) 1.06±0.05 1.08±0.09 1.19±0.08* 1.08±0.05§ 
Liver weight (%BW) 4.93±0.25 4.59±0.45 5.23±0.28 4.88±0.31 
Gastrocnemius weight (%BW)  1.04 ±0.08 1.08 ± 0.11 1.22 ± 0.06 1.09 ± 0.06 
 
Data are means±S.E.M.   * p<  0.01 vs Control  § p<  0.05 vs HFHS 
BW: body weight 
 TABLE 2 
Effects of diet and pHBSP chronic administration on mouse blood chemistry  
 
Control 
(n = 12) 
Control+pHBSP 
(n = 6) 
HFHS 
(n = 12) 
HFHS+pHBSP 
(n = 12) 
Triglycerides, mmol/L 0.52±0.08§ 0.54±0.09§ 1.02±0.07* 0.63±0.03§ 
Total cholesterol, mmol/L 2.30±0.09§ 2.54±0.11 2.66±0.09* 2.16±0.08§ 
LDL, mmol/L 0.65±0.17§ 0.61±0.09§ 1.08±0.18* 0.78±0.09§ 
HDL, mmol/L 1.83±0.14 1.81±0.25 1.19±0.17* 2.04±0.17§ 
Adiponectin, ng/mL 12.32±0.69§ 11.92±1.18§ 7.51±0.35* 10.76±0.63§ 
Leptin, pg/mL 33.56±2.06§ 34.53±2.87§ 58.36±3.87* 38.78±6.81§ 
 
 
Data are means±S.E.M.   * p<  0.01 vs Control   § p<  0.01 vs HFHS 
 
 
FIGURE LEGENDS: 
 
Figure 1. Effects of high-fat high-sugar (HFHS) diet and chronic administration of pHBSP (30 
µg/kg, s.c.) on serum insulin (Panel A), blood glucose (Panel B) and oral glucose tolerance (Panel 
C). Values are mean±S.E.M of 6 animals per group.  P < 0.05 vs Control. 
 
Figure 2. Effects of high-fat high-sugar (HFHS) diet and pHBSP administration on kidney structure 
and function. Representative pictures (Panel A) from mice maintained on the control diet or the 
HFHS diet and treated with pHBSP (30 µg/kg, s.c.). Kidneys from mice fed with a standard 
laboratory chow showed a normal appearance in the presence or absence of drug treatment. The 
HFHS diet produced an intense vacuolar degeneration of the S1 and S2 portions of the proximal 
convoluted tubules. These alterations were significantly attenuated by pHBSP administration. 
(arrows point S1 and S2 portions of the proximal convulted tubules; asterisks indicate tubular cells 
with vacuolar degeneration). Urinary albumin:creatinine ratio (ACR; Panel B) and blood urine 
nitrogen (BUN; Panel C) levels were measured in mice exposed to the control diet or the HFHS diet 
in the absence or presence of pHBSP (30 µg/kg, s.c.).. Values are mean±S.E.M of 6 animals per 
group.  P < 0.05 vs Control  p < 0.05 versus HFHS.  
 
Figure 3. Effects of high-fat high-sugar (HFHS) diet and pHBSP administration on liver lipid 
accumulation. Panel A: representative _40 magnification photomicrographs of Oil Red O staining 
on liver sections from mice maintained on the control diet or the HFHS diet and treated with 
pHBSP (30 µg/kg, s.c.). Arrows point hepatocytes with lipid droplets. Panel B: triglyceride (TG) 
content in mouse liver. Data are mean±S.E.M of 6 animals per group.  P < 0.05 vs Control  p < 
0.05 versus HFHS.  
 
Figure 4. Alterations in insulin signalling pathway in the skeletal muscle of mice maintained on 
HFHS diet in the absence or presence of pHBSP. Total protein expression of IRS-1 (Panel A), Akt 
(Panel B), and GSK-3β (Panel C) as well as their related phosphorylated forms were analyzed by 
Western blot on the gastrocnemius homogenates obtained from mice exposed to the control diet or 
the HFHS diet and treated with pHBSP (30 µg/kg, s.c.). Protein expression is measured as relative 
optical density (O.D.), corrected for the corresponding tubulin contents and normalized to the 
Control band. The data are means ± S.E.M. of three separate experiments.  p < 0.05 versus 
Control;  p < 0.05 versus HFHS. 
 
Figure 5. Effects of dietary manipulation and pHBSP treatment on GLUT-4 localization (Panel A, 
original magnification: 400x) and expression (Panel B), AS160 total protein expression and Thr642 
phosphorylation (Panel C) and glycogen content (Panel D) in the skeletal muscle from mice 
exposed to the control diet or the HFHS diet and treated with pHBSP (30 µg/kg, s.c.). Protein 
expression is measured as relative optical density (O.D.), corrected for the corresponding tubulin 
and normalized using the related Control band. Data are means ± S.E.M. of three separate 
experiments for Western blot analysis and 6-8 animals per group for skeletal muscle glycogen 
content.  p < 0.05 versus Control;  p < 0.05 versus HFHS.  
 
Figure 6. Effects of pHBSP on local and systemic levels of IL-6 and FGF-21 in mice fed with a 
HFHS diet. IL-6 and FGF-21 concentrations were analyzed by ELISA in gastrocnemius 
homogenates (Panels A and B, respectively) and serum (Panels C and D, respectively) of mice 
maintained on the control or the HFHS diet and treated with pHBSP (30 µg/kg, s.c.). Data are 
means ± S.E.M. of 6-8 animals/group.  p < 0.05 versus Control;  p < 0.05 versus HFHS.  
 
Figure 7. Effects of pHBSP treatment on markers of mitochondrial production/biogenesis in the 
gastrocnemius of mice fed with a HFHS diet. Cytochrome c oxidase-1 (COI, Panel A), peroxisome 
proliferator-activated receptor γ co-activator 1-α (PGC1-α, Panel B), mitochondrial transcription 
factor A (mtTFA, Panel C) and nuclear respiratory factor-1 (NRF-1, Panel D) protein expression 
was analysed by Western blot on the gastrocnemius homogenates obtained from mice maintained 
on the control or the HFHS diet and treated with pHBSP (30 µg/kg, s.c.). Protein expression is 
measured as relative optical density (O.D.), corrected for the corresponding tubulin contents and 
normalized using the related Control band. The data are means ± S.E.M. of three separate 
experiments.  p < 0.05 versus Control;  p < 0.05 versus HFHS.  
 
Figure 8. Heterodimerization between EpoR and βcR in the mouse skeletal muscle. Co-
immunoprecipitation analysis illustrating the heteromeric complex consisting of EpoR and βcR in 
gastrocnemius homogenates obtained from mice maintained on the control or the HFHS diet and 
treated with pHBSP (30 µg/kg, s.c.). Lysate from skeletal muscles were subjected to 
immunoprecipitation (IP) with anti-EpoR antibody and then exposed to immunoblot (IB) analysis 
with either anti-EpoR (left panel) or anti- βcR antibodies (right panel). The results, representative of 
two independent experiments, show interaction between the two receptors both in control condition 
and after dietary manipulation and/or pHBSP treatment.  
 
  
 
 
 
 
 
 
 
